Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.607156
Title: SPARC, a matricellular protein that protects cancer from therapy
Author: Santangelo, Alessandra
ISNI:       0000 0004 5362 2735
Awarding Body: Open University
Current Institution: Open University
Date of Award: 2014
Availability of Full Text:
Access through EThOS:
Abstract:
The matricellular protein SP ARC (secreted protein acidic and rich in cysteine) is a master regulator of tissue stroma; it is expressed during tissue remodeling and repair and its impaired regulation has a role in fibrotic responses, in determining the composition of the tumor-associated stroma and, less expected, in regulating the immune response. The complexity of studying SP ARC in cancer stems from its concomitant or alternative expression in tumor and/or stroma cells depending on the tumor histotypes. Extracellular matrix (ECM) gene profile of human breast carcinomas correlates SP ARC expression with prognosis and response to therapy. In particular, a subgroup of breast tumors can be identified based on ECM gene signature headed by SP ARC that correlates with tumor grade, bad prognosis and poor response to therapy. Epithelial to mesenchymal transition (EMT) has been associated to drug resistance and SPARC has been implicated in EMT. Nevertheless the source of SP ARC and its path toward EMT and the associated drug resistance have not been identified yet. I have used a well-defined model of transgenic mouse mammary carcinoma expressing the mutated rat oncogene c-erB2 (HER-2/neu), under the mouse mammary turn or virus promoter, backcrossed with Sparc-I - mice to establish mammary carcinoma cell lines devoid of SP ARC expression, in which SP ARC can be restored by retroviral gene transduction. With this isogenic cell lines I have been able to show that SP ARC expression in tumor cells induces EMT only in vivo, indicating that EMT is a micro environmental and not a cell autonomous process. Moreover, SP ARC expressing tumors became resistant to treatment with Doxil (Doxil, a pegylated form of Doxorubicin). Investigating the environmental players responsible of EMT in SP ARC transduced tumors, I found that myeloid cells and particularly the so called myeloid derived suppressor cells (MDSC) have a role in EMT and drug resistance depending on SP ARC. SP ARC does not change the number or ratio between the Ly60high and the Ly6010w fractions ofCD11b MDSC rather it detelmines the immunosuppressive phenotype of recruited myeloid cells. The data show that SPARC-forced expression increased the activation of pro-turn oral (CCL2, CCLS) and immunosuppressive (ArgI, NOS2, Cox-2) genes in monocyte-MDSC (the Ly6010w fraction). Furthermore, the role of myeloid cells recruited in Doxil resistance and EMT has been proven adding bisphosphonate to Doxil during treatment. , Bisphosphonates have been shown to inhibit induction and function of myeloid suppressor cells. Indeed, Bisphosphonates addition reverted EMT, the immunosuppressive phenotype of myeloid cells and rendered SP ARC-producing tumors sensitive to Doxil administration.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.607156  DOI: Not available
Share: